Navigation

TA107 Breast cancer (early) - trastuzumab: guidance

The published full guidance on trastuzumab (herceptin) for the adjuvant treatment of early-stage HER2-positive breast cancer. It presents the recommendations in a format suited to implementation by health professionals and NHS bodies.

Correction

It has been brought to our attention that this guidance contained an error in section 1.3, where it stated that:

‘Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then trastuzumab treatment should be suspended…’

This has now been amended so that it follows more closely the SPC for trastuzumab, as follows:

‘Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10 percentage (ejection) points or more from baseline and to below 50% then trastuzumab treatment should be suspended…’

Electronic versions of the guidance have been amended below. Printed copies of the amended quick reference guide will be available shortly from the NHS Response Line; telephone 0870 1555 455 and quote reference number N1111.

This page was last updated: 28 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.